Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) SVP Sells 4,772 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Thomas Andrew Rowland sold 4,772 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total transaction of $357,470.52. Following the completion of the sale, the senior vice president owned 38,730 shares in the company, valued at $2,901,264.30. The trade was a 10.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP traded down $2.00 during trading hours on Friday, reaching $70.49. 517,923 shares of the company’s stock were exchanged, compared to its average volume of 360,579. The company has a market capitalization of $1.58 billion, a P/E ratio of 20.98 and a beta of 0.52. ANI Pharmaceuticals, Inc. has a 12 month low of $56.71 and a 12 month high of $99.50. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11. The business’s 50-day simple moving average is $79.12 and its two-hundred day simple moving average is $85.35.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Assenagon Asset Management S.A. boosted its position in ANI Pharmaceuticals by 259.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 46,328 shares of the specialty pharmaceutical company’s stock worth $4,244,000 after acquiring an additional 33,438 shares during the period. Campbell & CO Investment Adviser LLC acquired a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at about $1,597,000. Decker Retirement Planning Inc. lifted its position in shares of ANI Pharmaceuticals by 76,862.5% in the third quarter. Decker Retirement Planning Inc. now owns 36,942 shares of the specialty pharmaceutical company’s stock worth $3,384,000 after purchasing an additional 36,894 shares in the last quarter. Intech Investment Management LLC boosted its holdings in shares of ANI Pharmaceuticals by 134.7% during the second quarter. Intech Investment Management LLC now owns 26,917 shares of the specialty pharmaceutical company’s stock worth $1,756,000 after purchasing an additional 15,447 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in ANI Pharmaceuticals during the second quarter valued at approximately $2,137,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Guggenheim lifted their price target on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, Barclays initiated coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price objective for the company. Six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $103.43.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.